Literature DB >> 16130195

Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients.

Yong Liu1, Li Chen, Shu-You Peng, Zhou-Xun Chen, C Hoang-Vu.   

Abstract

OBJECTIVES: To explore the mechanism of development and aggressiveness in gastric carcinomas by investigating the expression and role of CD97 and its cellular ligand CD55 in gastric carcinomas.
METHODS: Tumor and corresponding normal mucosal tissue, collected from 39 gastric carcinoma patients, were examined by immunohistochemistry and RT-PCR for the expression of CD97 and CD55.
RESULTS: CD97(stalk) was strongly stained on scattered tumor cells or small tumor cell clusters at the invasion front of gastric carcinomas. The expression of CD97(stalk) was frequently observed in tumors of stage I and T1 gastric carcinoma patients. The expression of CD97(stalk) between Stage I and Stage II, III, IV specimens showed significant difference (P<0.05), between T1 and T2, T3, T4 specimens also showed significant difference (P<0.05). Specimens with tumor invasion depth limited in mucosa of T1 specimens showed higher positive CD55 expression than specimens with the same tumor invasion depth in T2, T3, T4 specimens, the expression of CD55 between T1 and T2, T3, T4 specimens was significantly different (P<0.05). There was strong correlation between the distribution patterns of CD97(stalk) and CD55 on tumor tissues (r=0.73, P<0.05). Signet ring cell carcinomas frequently contained strong CD97(stalk) and CD55-staining.
CONCLUSIONS: Our results suggest that CD97(stalk) is probably involved in the growth, invasion and aggressiveness of gastric carcinomas by binding its cellular ligand CD55. CD97(stalk) and CD55 could be useful as molecular markers for prognosis and therapy of gastric carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130195      PMCID: PMC1389911          DOI: 10.1631/jzus.2005.B0913

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  19 in total

1.  CD97: a dedifferentiation marker in human thyroid carcinomas.

Authors:  G Aust; W Eichler; S Laue; I Lehmann; N E Heldin; O Lotz; W A Scherbaum; H Dralle; C Hoang-Vu
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

Authors:  W Remmele; H E Stegner
Journal:  Pathologe       Date:  1987-05       Impact factor: 1.011

3.  Regulation of CD97 protein in thyroid carcinoma.

Authors:  C Hoang-Vu; K Bull; I Schwarz; G Krause; C Schmutzler; G Aust; J Köhrle; H Dralle
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

Review 4.  The EGF-TM7 family: unusual structures at the leukocyte surface.

Authors:  A J McKnight; S Gordon
Journal:  J Leukoc Biol       Date:  1998-03       Impact factor: 4.962

5.  Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front.

Authors:  T Brabletz; A Jung; K Hermann; K Günther; W Hohenberger; T Kirchner
Journal:  Pathol Res Pract       Date:  1998       Impact factor: 3.250

6.  N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding.

Authors:  Manja Wobus; Björn Vogel; Eike Schmücking; Jörg Hamann; Gabriela Aust
Journal:  Int J Cancer       Date:  2004-12-10       Impact factor: 7.396

7.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

8.  Expression of CD97 and CD55 in human medullary thyroid carcinomas.

Authors:  Tarek Mustafa; Thomas Klonisch; Sabine Hombach-Klonisch; Astrid Kehlen; Cornelia Schmutzler; Josef Koehrle; Oliver Gimm; Henning Dralle; Cuong Hoang-Vu
Journal:  Int J Oncol       Date:  2004-02       Impact factor: 5.650

Review 9.  The EGF-TM7 family: a postgenomic view.

Authors:  Mark J Kwakkenbos; Else N Kop; Martin Stacey; Mourad Matmati; Siamon Gordon; Hsi-Hsien Lin; Jörg Hamann
Journal:  Immunogenetics       Date:  2003-11-27       Impact factor: 2.846

10.  The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF).

Authors:  J Hamann; B Vogel; G M van Schijndel; R A van Lier
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  13 in total

1.  The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.

Authors:  Shao-Liang Han; Chang Xu; Xiu-Ling Wu; Jun-Lin Li; Zhi Liu; Qi-Qiang Zeng
Journal:  Int J Colorectal Dis       Date:  2010-03-26       Impact factor: 2.571

2.  Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment.

Authors:  Jelena Vasilevska; Gustavo Antonio De Souza; Maria Stensland; Dace Skrastina; Dmitry Zhulenvovs; Raimonds Paplausks; Baiba Kurena; Tatjana Kozlovska; Anna Zajakina
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

3.  CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway.

Authors:  Chao Li; Da-Ren Liu; Guo-Gang Li; Hou-Hong Wang; Xiao-Wen Li; Wei Zhang; Yu-Lian Wu; Li Chen
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 4.  Cancer stem cells as targets for cancer therapy: selected cancers as examples.

Authors:  Sabine Hombach-Klonisch; Ted Paranjothy; Emilia Wiechec; Paola Pocar; Tarek Mustafa; Anja Seifert; Christian Zahl; Klaus Luis Gerlach; Katharina Biermann; Klaus Steger; Cuong Hoang-Vu; Klaus Schulze-Osthoff; Marek Los
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

5.  Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma.

Authors:  Jinsheng Wu; Liu Lei; Shaochuang Wang; Dianhua Gu; Jianhuai Zhang
Journal:  J Biomed Biotechnol       Date:  2012-04-03

6.  The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma.

Authors:  Daren Liu; Bogusz Trojanowicz; Longyun Ye; Chao Li; Luqing Zhang; Xiaowen Li; Guogang Li; Yixiong Zheng; Li Chen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells.

Authors:  Michael Safaee; Shayan Fakurnejad; Orin Bloch; Aaron J Clark; Michael E Ivan; Matthew Z Sun; Taemin Oh; Joanna J Phillips; Andrew T Parsa
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

8.  Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer.

Authors:  Zheng He; Hui Wu; Yanli Jiao; Jun Zheng
Journal:  Oncol Lett       Date:  2014-12-01       Impact factor: 2.967

9.  A voting approach to identify a small number of highly predictive genes using multiple classifiers.

Authors:  Md Rafiul Hassan; M Maruf Hossain; James Bailey; Geoff Macintyre; Joshua W K Ho; Kotagiri Ramamohanarao
Journal:  BMC Bioinformatics       Date:  2009-01-30       Impact factor: 3.169

10.  CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent.

Authors:  Daren Liu; Chao Li; Bogusz Trojanowicz; Xiaowen Li; Dike Shi; Chenni Zhan; Zhefang Wang; Li Chen
Journal:  Gastric Cancer       Date:  2015-08-02       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.